Clinical Trial

Probiotics in Mild Alzheimer's Disease

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-19.
Trial Details
NCT Number NCT06181513
Lead Sponsor University of Nicosia
Collaborators: Cyprus Institute of Neurology and Genetics
Conditions Neurodegenerative Diseases, Cognition Disorders in Old Age
Enrollment 40 participants
Start Date 2022-12-19
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-05